Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer

Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer

PURPOSE Women with recurrent, multiply-treated epithelial ovarian cancer (EOC) have unfavorable prognosis with limited treatment options after failure of platinum-based regimens. We report here a retrospective analysis of women with recurrent, platinum-resistant EOC treated with an oral regimen of p...

Full description

Bibliographic Details
Main Authors: Seema Gulia, Jaya Ghosh, Jyoti Bajpai, Sushmita Rath, Amita Maheshwari, T.S. Shylasree, Kedar Deodhar, Meenakshi Thakur, Sudeep Gupta
Format: Article
Language:English
Published: American Society of Clinical Oncology 2020-11-01
Series:JCO Global Oncology
Online Access:https://ascopubs.org/doi/10.1200/JGO.19.00331

Internet

https://ascopubs.org/doi/10.1200/JGO.19.00331

Similar Items